The conclusions from the in vivo studies still support the evidence that the application of a Drp1 inhibitor with Mdivi-1 after cerebral ischemia has the benefits of decreasing mitochondrial fission, neuronal death, neurological deficit, and improving the recovery of brain function. The gene discussed is DNM1L; the disease is brain ischemia.